Mazdutide

What Is Mazdutide and What Is It Used For?

Mazdutide is a once-weekly GLP-1 and glucagon receptor dual agonist developed by Innovent Biologics, also known as IBI362 or LY3305677, positioned in the metabolic and weight-loss peptide category for its combined effects on appetite regulation, energy expenditure, and hepatic lipid metabolism. It is primarily studied for weight reduction, liver fat management, and glycaemic control in type 2 diabetes. Mazdutide was first approved in China in June 2025 for chronic weight management and later approved in September 2025 for glycaemic control in adults with type 2 diabetes. As of June 2026, Mazdutide is not approved by the FDA, EMA, or TGA, and should be described as investigational outside China.

GLP-1 receptor activity supports appetite suppression, slower gastric emptying, and glucose-dependent insulin secretion, overlapping with established therapies such as Semaglutide and Tirzepatide. Glucagon receptor activity is hypothesized to contribute to increased energy expenditure and liver fat reduction, which is the basis for Mazdutide’s differentiated positioning relative to pure GLP-1 agonists.

Mazdutide Mechanism of Action: GLP-1 and Glucagon Receptor Dual Agonism

Mazdutide activates two receptor pathways with distinct but complementary proposed metabolic roles.

• GLP-1 Receptor Agonism: Supports appetite suppression, slowed gastric emptying, glucose-dependent insulin secretion, and post-meal glucose regulation. This pathway aligns with the established mechanisms of approved GLP-1 therapies.
• Glucagon Receptor Agonism: Glucagon receptor activity is hypothesized to contribute to increased energy expenditure and liver fat reduction through hepatic lipid metabolism pathways. This is the primary proposed differentiator from pure GLP-1 receptor agonists and the basis for liver fat as a research focus. These effects should be understood as a research rationale rather than proven universal outcomes.

Together, GLP-1-mediated appetite reduction and glucagon-linked energy expenditure create a two-pathway metabolic profile targeting weight loss, glucose control, and liver fat reduction. Mazdutide and Retatrutide both include glucagon receptor activity, while Semaglutide does not. Retatrutide additionally activates the GIP receptor, making it a three-pathway agent compared with Mazdutide’s two-pathway approach.

Mazdutide Peptide Benefits and Clinical Data

Weight Reduction (Phase 2, trial-derived)

In a 2023 Phase 2 randomized, double-masked, placebo-controlled trial published in Nature Communications, Chinese adults with overweight or obesity received once-weekly Mazdutide at 3 mg, 4.5 mg, or 6 mg, or placebo, for 24 weeks. Mean percentage change from baseline in body weight was −6.7% with 3 mg, −10.4% with 4.5 mg, and −11.3% with 6 mg, compared with +1.0% with placebo. Treatment difference versus placebo ranged from −7.7% to −12.3%. Common adverse events included diarrhea, nausea, and upper respiratory tract infection.

Glycaemic Control in Type 2 Diabetes (Phase 3, trial-derived)

Phase 3 data published in Nature reported that Mazdutide 4 mg and 6 mg significantly reduced HbA1c versus placebo at week 24. Weight loss from baseline was −5.61% with 4 mg and −7.81% with 6 mg, compared with −1.26% with placebo.

Exploratory Liver Fat Findings (Phase 3, exploratory analysis)

In the GLORY-1 Phase 3 weight-management study presented at the American Diabetes Association Scientific Sessions in 2024, exploratory analyses reported reductions in liver fat content with Mazdutide 4 mg and 6 mg in Chinese adults with overweight or obesity. These findings were not the primary endpoint of the trial and should be framed as exploratory rather than established efficacy data.

Is Mazdutide Better Than Tirzepatide? Dosage and Dosing Chart

No head-to-head randomized controlled trial has directly compared Mazdutide and Tirzepatide. The comparison is primarily mechanistic: Mazdutide targets GLP-1 and glucagon receptors, while Tirzepatide targets GLP-1 and GIP receptors.

The secondary pathway differs: Mazdutide’s glucagon component is hypothesized to contribute to energy expenditure and liver fat reduction, whereas Tirzepatide’s GIP component influences incretin signaling and adipose metabolism. Tirzepatide currently holds FDA approval with a broader regulatory evidence base.

Mazdutide Dosage and Dosing Chart

No approved dosing protocol exists outside China. All references below are trial-derived and should not be interpreted as prescribing guidance.

• 3 mg, 4.5 mg, 6 mg once weekly subcutaneous: studied in Phase 2 obesity trials over 24 weeks
• 4 mg, 6 mg once weekly subcutaneous: used in Phase 3 obesity and type 2 diabetes studies, including the GLORY and DREAMS programs

Gradual dose titration is used in trial settings to manage gastrointestinal tolerability. Storage references in trial settings include refrigeration at 2–8°C, protection from light, and avoidance of freezing. Final handling should always follow product-specific documentation.

Mazdutide Side Effects and Safety Profile

Mazdutide side effects in published trial data are broadly consistent with the GLP-1/glucagon receptor agonist class. Common adverse events reported in the Phase 2 obesity trial include nausea, diarrhea, vomiting, decreased appetite, and upper respiratory tract infection, typically arising during dose escalation.

Glucagon receptor co-activation is a theoretical consideration for heart rate effects in susceptible individuals; however, specific cardiovascular safety data for Mazdutide should be verified against trial publications before any clinical discussion, as direct human safety data confirming this effect for Mazdutide specifically are not confirmed in the sources reviewed here.

Long-term and broader-population safety data remain pending further Phase 3 and post-approval data, particularly for populations outside China. Safety claims should remain trial-specific and evidence-qualified throughout any protocol discussion.

Legal Status of Mazdutide

Information current as of June 2026. The regulatory landscape for Mazdutide is evolving rapidly. Practitioners should verify the current status directly with the relevant authority in their jurisdiction.

• China: Mazdutide was first approved in June 2025 for chronic weight management in adults with overweight or obesity, and later in September 2025 for glycaemic control in adults with type 2 diabetes. Practitioners should verify current approved indications and labeling.
• United States: As of June 2026, Mazdutide is not FDA-approved and is classified as investigational. It is not available for clinical prescribing outside registered trial settings in the US.
• European Union: As of June 2026, Mazdutide is not EMA-approved. No approved regulatory pathway exists in the EU at the time of writing.
• Australia: As of June 2026, Mazdutide is not TGA-approved. Practitioners should verify the current TGA status before any research planning or patient-facing discussion.

Mazdutide vs Retatrutide, Tirzepatide, and Semaglutide

Retatrutide

Mazdutide and Retatrutide both include glucagon receptor activity, while Semaglutide does not, making liver fat reduction and energy expenditure relevant to both mechanisms. The key difference is that Retatrutide adds GIP receptor activity as a third pathway, which may broaden incretin and adipose-related signaling beyond what the GLP-1/glucagon combination achieves. Neither compound is FDA-approved as of June 2026, and head-to-head data are not available.

Practitioners who buy Retatrutide for research are evaluating a three-pathway mechanism that extends glucagon activity with additional GIP signaling, compared with Mazdutide’s more focused two-pathway approach.

Tirzepatide

Mazdutide and Tirzepatide both activate the GLP-1 receptor, but their second receptor targets differ in a clinically meaningful way. Mazdutide adds glucagon receptor activity, which is hypothesized to contribute to energy expenditure and hepatic lipid metabolism, while Tirzepatide adds GIP receptor activity and has a stronger current regulatory standing. Tirzepatide carries FDA approval for type 2 diabetes and chronic weight management, while Mazdutide remains investigational outside China.

Practitioners who buy Tirzepatide for research are working with an approved compound that targets a different secondary receptor than Mazdutide, making the two agents complementary in research scope rather than direct substitutes.

Semaglutide

Semaglutide is a pure GLP-1 receptor agonist with established regulatory approvals across multiple markets for type 2 diabetes and weight management. Mazdutide adds glucagon receptor activity as a second pathway, distinguishing it from Semaglutide through its hypothesized contributions to energy expenditure and liver fat metabolism that a GLP-1-only agent does not address. Semaglutide remains the most extensively studied reference point in the GLP-1 class.

Practitioners who buy Semaglutide for research are using the established single-pathway benchmark to position emerging dual-agonist agents like Mazdutide in context.

Mazdutide sits between approved GLP-1 or GLP-1/GIP agents and broader investigational triple agonists. Choice between compounds depends on regulatory availability, receptor target, evidence maturity, patient profile, and whether the research objective prioritizes appetite control, glycaemic control, liver fat reduction, or overall weight loss.

Where Can Practitioners Buy Mazdutide Online?

Mazdutide is available for research purposes to qualified professionals only and is not intended for general consumer use outside of approved jurisdictions. Whether evaluating an individual purchase or exploring wholesale arrangements for institutional research use, practitioners should prioritize suppliers that can provide verifiable purity documentation, LOT number traceability, and a current certificate of analysis for each batch.

Before placing an order, practitioners should confirm that the supplier meets applicable research-use and documentation standards in their jurisdiction. Doctor Medica supports licensed professionals by offering sourcing guidance and access to relevant documentation.

Practitioners looking to buy Mazdutide from a verified research-grade supplier are encouraged to contact Doctor Medica’s staff for guidance and directions.

FAQs

1. What is Mazdutide?

Mazdutide is a GLP-1 and glucagon receptor dual agonist developed by Innovent Biologics, positioned in the metabolic and weight-loss peptide category for its combined effects on appetite regulation, energy expenditure, and liver fat metabolism. It received its first approval in China in June 2025, and as of June 2026, it remains investigational in the US, EU, and Australia.

2. What does the Mazdutide peptide do?

Mazdutide activates GLP-1 receptors to support appetite suppression, slowed gastric emptying, and glucose-dependent insulin secretion, while glucagon receptor activity is hypothesized to contribute to energy expenditure and liver fat reduction. These mechanisms support its evaluation in protocols for weight reduction, liver fat management, and type 2 diabetes.

3. What is Mazdutide used for?

Mazdutide is approved in China for chronic weight management and glycaemic control in adults with type 2 diabetes as of late 2025. Outside China, it should be described as investigational. Clinical trial data support its evaluation for weight reduction and metabolic disease management, and exploratory analyses suggest liver fat findings that require further investigation.

4. What is the Mazdutide dosage?

In Phase 2 trials, Mazdutide was studied at 3 mg, 4.5 mg, and 6 mg once weekly subcutaneously. Phase 3 studies evaluated 4 mg and 6 mg once weekly. Gradual dose escalation is used to manage tolerability. No approved dosing protocol exists outside China, and all referenced doses are trial-derived.

5. Is Mazdutide better than Tirzepatide?

No head-to-head randomized controlled trial has directly compared Mazdutide and Tirzepatide. Mazdutide targets GLP-1 and glucagon receptors, while Tirzepatide targets GLP-1 and GIP receptors. Tirzepatide currently holds FDA approval with a broader regulatory evidence base. Mechanistic differences in the secondary receptor pathway drive distinct metabolic profiles rather than a clear claim of superiority.

6. How does Mazdutide compare to Retatrutide?

Mazdutide is a dual agonist targeting GLP-1 and glucagon receptors, while Retatrutide is a triple agonist that also targets the GIP receptor. Both include glucagon receptor activity relevant to research on liver fat and energy expenditure. Mazdutide represents a focused two-pathway approach, while Retatrutide adds a third pathway. Neither is FDA-approved as of June 2026.

7. Is Mazdutide legal?

Mazdutide was first approved in China in June 2025 for chronic weight management and later approved in September 2025 for glycaemic control in adults with type 2 diabetes. As of June 2026, it is not FDA-approved, EMA-approved, or TGA-approved. Practitioners should verify current jurisdiction-specific status before any clinical, research, or procurement discussion.

References

1. Shirley M. Mazdutide: First Approval. Drugs. 2025;85(12):1621-1627. doi:10.1007/s40265-025-02249-y
2. Zhu D, Zhao J, Cai H, et al. Mazdutide versus placebo in Chinese adults with type 2 diabetes. Nature. 2026;652(8108):174-180. doi:10.1038/s41586-025-10026-w
3. Ji L, Jiang H, Cheng Z, et al. A phase 2 randomised controlled trial of mazdutide in Chinese overweight adults or adults with obesity. Nat Commun. 2023;14(1):8289. Published 2023 Dec 14. doi:10.1038/s41467-023-44067-4

For licensed medical professionals only. This content is for informational purposes only and does not constitute medical advice.